Comments
yourfanat wrote: I am using another tool for Oracle developers - dbForge Studio for Oracle. This IDE has lots of usefull features, among them: oracle designer, code competion and formatter, query builder, debugger, profiler, erxport/import, reports and many others. The latest version supports Oracle 12C. More information here.
Cloud Expo on Google News

2008 West
DIAMOND SPONSOR:
Data Direct
SOA, WOA and Cloud Computing: The New Frontier for Data Services
PLATINUM SPONSORS:
Red Hat
The Opening of Virtualization
GOLD SPONSORS:
Appsense
User Environment Management – The Third Layer of the Desktop
Cordys
Cloud Computing for Business Agility
EMC
CMIS: A Multi-Vendor Proposal for a Service-Based Content Management Interoperability Standard
Freedom OSS
Practical SOA” Max Yankelevich
Intel
Architecting an Enterprise Service Router (ESR) – A Cost-Effective Way to Scale SOA Across the Enterprise
Sensedia
Return on Assests: Bringing Visibility to your SOA Strategy
Symantec
Managing Hybrid Endpoint Environments
VMWare
Game-Changing Technology for Enterprise Clouds and Applications
Click For 2008 West
Event Webcasts

2008 West
PLATINUM SPONSORS:
Appcelerator
Get ‘Rich’ Quick: Rapid Prototyping for RIA with ZERO Server Code
Keynote Systems
Designing for and Managing Performance in the New Frontier of Rich Internet Applications
GOLD SPONSORS:
ICEsoft
How Can AJAX Improve Homeland Security?
Isomorphic
Beyond Widgets: What a RIA Platform Should Offer
Oracle
REAs: Rich Enterprise Applications
Click For 2008 Event Webcasts
SYS-CON.TV
Top Links You Must Click On


Arecor Awarded Biomedical Catalyst Funding Towards £1.3 Million Project

CAMBRIDGE, England, November 6, 2012 /PRNewswire/ --

Cambridge biotech company Arecor has been awarded £785,000 from the government-backed Biomedical Catalyst Fund to accelerate the development of high concentration antibodies to allow more convenient administration of our future therapeutic medicines and reduce healthcare costs. Arecor has recently demonstrated Proof of Concept in developing stable aqueous formulations of a number of high concentration monoclonal antibodies.

The award was announced by Technology Strategy Board on Sunday, 4th November 2012 and is one of 32 projects awarded funding totalling £39 million. These are the first substantial awards made from the £180 million Biomedical Catalyst programme managed by the Technology Strategy Board and the Medical Research Council.

Arecor is a pioneer in the stabilisation of biologic molecules, a key challenge in the development of many therapeutic proteins, vaccines and diagnostics. Many proteins, peptides or vaccines are too unstable in liquid form to develop ready-to-use drugs or are unstable at high concentrations.  Arecor has developed a set of unique technologies to address these problems with the potential to revolutionise the development, use and distribution of the next generation of therapeutic medicines.  

Tom Saylor, CEO of Arecor, said the award will go towards a £1.3 million project to drive forward their innovative research:

"Arecor is delighted to have been awarded an inaugural Biomedical Catalysts funding from the Technology Strategy Board which justifies our position as a leader in the field of stable aqueous formulation and confidence in our platform for stabilising anitbody therapies at high concentration, as well as  recognising the expertise of our dedicated scientists."

David Willetts, Minister for Universities and Science, said:

"Britain is in a global race today and this £39 million investment will help keep us at the very forefront of life sciences by supporting some of our most innovative SMEs and universities. It will help take excellent ideas through to market, driving growth and helping patients benefit from the very latest technologies and treatments."

The ground  breaking work carried  out using Arecor's patented formulation technology can enable new and better medicines and vaccines.  From its work on over 60 biological molecules, Arecor has developed proprietary technologies to address most of the pathways that lead these products to degrade in storage.  

Arecor's unique technology also enables the development of high concentration forms of antibodies to simplify and reduce the costs of current treatments, which currently require visits to hospitals for administration. This will enable a shift from unsatisfactory outpatient intravenous infusions presently used in clinics to the provision of a ready-to-use autoinjector or simple injection. The benefits of self-administration include increased treatment satisfaction, convenience and improved healthcare costs.

Iain Gray, Chief Executive of the Technology Strategy Board, added:

"We have been hugely impressed by the number and quality of applications, which just goes to show the strength, vitality and innovative spirit of the UK's world-leading life sciences industry.  By providing vital finance to help at least some of these companies to evaluate, develop and demonstrate their exciting healthcare innovations, the Biomedical Catalyst is helping to turn promising ideas into innovative technologies faster, so providing greater benefits to patients through improvements in health outcomes."

Notes to Editors:

1. Further information about Arecor can be found out: http://www.arecor.com/

2. For media enquiries, please contact Arecor press officer Ellee Seymour on +44(0)1353-648565

3. For Business Development enquiries, please contact Guy Hill on info@arecor.com  



About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Enterprise Open Source Magazine Latest Stories . . .
The OpenNebula Project has just announced the Beta release of vOneCloud, a CentOS Linux virtual appliance for vSphere that contains all required OpenNebula services optimized to work on existing VMware vCenter deployments. vOneCloud is for companies that want to create a self-service c...
Code-named “Fox Fur”, the twenty-third release of OpenNebula is available today with complete support to build clouds on existing VMware environments. OpenNebula 4.10 seamlessly integrates vCenter virtualized infrastructures leveraging the advanced features such as vMotion, HA or DRS s...
Let’s say we developed an application and plan to move our app to production on Amazon Elastic Cloud (EC2). Our application, in the form of a webapp, was developed using eclipse and we have tested it on Tomcat running locally. Now, we may want to test our app on an EC2 environment befo...
"Our premise is Docker is not enough. That's not a bad thing - we actually love Docker. At ActiveState all our products are based on open source technology and Docker is an up-and-coming piece of open source technology," explained Bart Copeland, President & CEO of ActiveState Software,...
This past week the Appcore team got the opportunity to attend one of the industry’s leading cloud events, Cloud Expo in Santa Clara, CA. We spent a lot of time interacting with attendees at the exhibit portion of the event. As a software company with a sole commitment to CloudStack, we...
As cloud gives an opportunity to businesses to buy services externally – how is cloud impacting your customers? In his General Session at 15th Cloud Expo, Fabio Gori, Director of Worldwide Cloud Marketing at Cisco, provided answers to big questions: Do you see hybrid cloud as where th...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021




SYS-CON Featured Whitepapers
ADS BY GOOGLE